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The Mexican beaded lizard (Heloderma horridum horridum) is one of the two
members of venomous lizards of the family Helodermatidae (suborder, sauria)
that inhabit the arid regions of the southwestern United States and the Pacific
coast of Mexico. The Heloderma venom is less well characterized than many
snake venoms. A neurotoxin (1), a hyaluronidase (2), peptides related to the
vasoactive intestinal peptide-secretin family (3, 4), and two arginine esterases (M,.
22,000 and 63,000) have been described. Mebs (5) has seen a kinin-generating
(or kallikrein-like) activity in the venom of the family member Gila monster
(Heloderma suspectum), but no purification to homogeneity or detailed character-
ization ofthis activity was achieved. In the following report we describe a protein
purification scheme that yields in two steps the electrophoretically homogeneous
arginine esterase (M, 63,000) from lyophilized H. h. horridum venom. Adetailed
examination of its catalytic activity revealed properties closely related to kalli-
krein.
Volume 164 December 1986 1835-1845
Materials and Methods
Microgranular DEAE-cellulose (DE-52) was from Whatman Inc., Clifton, NJ, and e-
aminocaproyl-p-aminobenzamidine agarose (benzamidine Sepharose) was from Pierce
Chemical Co., Rockford, IL. Diisopropylphosphofluoridate (DIFP), Omnifluor, and 1 .4-
his 2-(5-phenyloxazolyl) benzene (POPOP)' were purchased from New England Nuclear,
Boston, MA. All reagents for PAGE were obtained from Eastman Kodak Co., Rochester,
NY or Bio-Rad Laboratories, Richmond, CA. N-benzoyl-L-arginine ethyl ester (BAEE),
benzoyl-arginine-p-nitroanilide (BAPNA), 4-methyllumbelliferyl-p-guanidinobenzoate hy-
drochloride (MUGB) and 4-methyl-umbelliferone were purchased from Sigma Chemical
Co., St. Louis, MO . D-Pro-Phe-Arg p-nitroanilide (S-2302), D-Val-Leu-Arg-p-nitroanilide
(S-2266), D-Phe-Val-Arg p-nitroanilide (S-2160), and D-Glu-Gly-Arg p-nitroanilide (S-
Preliminary results ofthis work were presentedat theSymposiumon Animal Venoms andHemostasis,
July 20-21, 1985, San Diego, CA.; and they were published in abstract form (26). Address
correspondence to W.-D. Schleuning, Labortoire Central et Division d'Hematologie, CHUV, 1011
Lausanne, Switzerland.
' Abbreviations used in this paper:
￿
BAEE, N-benzoyl-L-arginine ethyl esther; BAPNA, benzoyl-
argininep-nitroanilide ; HMW, high molecularweight; MUGB, 4-methylumbelliferyl-p-guanidinoben-
zoate-hydrochloride; POPOP, 1,4-bis 2-(5-phenyloxazolyl) benzene; tPA, tissue-type plasminogen
activator.
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2227) were generous gifts of Dr. Petter Friberger, Kabi Vitrum, Stockholm, Sweden.
Soybean trypsin inhibitor and limabean trypsin inhibitor were from Sigma Chemical Co.
Aprotinin, the bovine pancreatic trypsin inhibitor ofthe Kunitz type (Trasylol), was kindy
provided by Dr. H. Truscheit, Bayer Pharmaceuticals, Wuppertal, Federal Republic of
Germany. Mainly single-chain, tissue-type plasminogen activator (tPA) was purified from
melanoma cell-conditioned medium, as described (6). Human high-molecular-weight
(HMW) kininogen was generously provided by Drs. Brigitte Dittmann and Hans Fritz,
University of Munich, Federal Republic of Germany.
Collection ofVenom.
￿
Heloderma venom was obtained by the technique initially described
by Loeb (7). Collected venom was separated into aliquots, lyophilized, and kept at -20°C
until further use (8).
Measurement of Enzymatic Activities.
￿
BAEE-hydrolyzing activity was measured as de-
scribed (8). Amidolytic activity vs. the substrates S-2302, S-2160, S-2227, S-2266, and
BAPNA was quantified by monitoring the increase of absorbance at 405 nm in a
spectrophotometer (Gilford Instrument Laboratories, Inc., Oberlin, OH) after the con-
ditions described by Latallo et al. (9). Km values were determined according to the double
reciprocal method of Lineweaver and Burk (9a), plotting data that were obtained after
least square analysis of the measured values. K; values were determined by measuring
substrate inhibitor competition according to Dixon (10). Active site titration was per-
formed with MUGB as described by Jameson et al . (11). Plasminogen activator activity
was determined by the "'I-fibrin lysis method of Unkeless et al. (12), and we determined
thrombin-like activity by standard methods in a clinical coagulometer. Kinin-liberating
activity was determined by incubating the enzyme with highly purified human HMW-
kininogen. The kinins formed were measured by monitoring the contractions of an
isolated rat uterus preparation using a polygraph recorder by a variation of the method
of Trautschold (13); 1 gg of helodermatine and 150 fcg of human HMW-kininogen were
incubated in 1 ml of 0.1 M Tris/HCI (pH 8.5), 10-i M phenanthroline for 30 min at
25°C. The reaction was stopped by heating the sample for 10 min at 95°C . The kinins
generated were quantified by comparing the activity with a standard curve, derived from
values obtained through the effects of 10-200 pg of synthetic bradykinin triacetate.
Column Chromatography.
￿
All procedures were performed in standard laboratory glass-
ware and polyethylene tubing connections at ambient temperature. Elution rates were
maintained constant by using peristaltic pumps. Fractions were collected in 10-ml glass
tubes.
Measurement of Protein Concentration.
￿
Protein concentrations were determined by the
method of Lowry et al. (14) or by absorbance measurements at 280 nm, assuming an
extinction coefficient of E2RO of 10.0.
Electrophoretic procedures. We performed SDS-PAGE using the conditions described by
Laemmli (15). 10% polyacrylamide slab gels (150 x 120 x 1 .5 mm) were used. Electro-
phoresis was performed at 25 mA constant current. Gels were fixed and stained in a
solution of 0.25% Coomassie Brilliant Blue R in 30% methanol (vol/vol), 10% acetic acid
(vol/vol) in double-distilled H2O. Destaining was achieved in a solution of 50% (vol/vol)
methanol, 10% (vol/vol) acetic acid in double-distilled H2O.
Iodination Procedure.
￿
2,ug of helodermatine were iodinated to a specific activity of -2
,uCi/g using New England Nuclear (Boston, MA) Bolton and Hunter reagent according
to the instructions provided by the manufacturers.
Labeling with DIFP.
￿
20 ng helodermatine were labeled at the active site with ["H]iPr2-
P-F, essentially as described (16).
Amino Acid Analysis.
￿
We performed amino acid analysis after acid hydrolysis of sample
duplicates according to Moore and Stein (17), as modified by Liao et al. (I8) to avoid
oxidation ofcysteine, methionine, and tyrosine . Serine and threonine values were obtained
by extrapolation to time 0 from the 24-, 48-, and 72-h hydrolysis time. Values for valine,
leucine, and isoleucine were obtained from the 72-h hydrolysis.
Amino Acid Sequence Determination.
￿
The amino terminal covalent structure of helod-
ermatine was determined by sequential chemical degradation as described by Edman (19),
applying the technical specifications of Hewick et al . (20).ALAGON ET AL.
￿
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FIGURE 1 .
￿
Benzamidine-Sepharose affinity chromatography of H. h . horridum whole venom.
Whole soluble venom (100 mg) was applied to the column. Elution rate was maintained 40
ml/h. 3-ml fractions were collected. The start of the gradient is indicated by an arrow (G).
Fractions were pooled as indicated by horizontal bars.
Blood Pressure Recording from the Carotid Artery of an Anesthetized Rabbit.
￿
A New
Zealand white rabbit (2.5 kg) was anesthetized with phenobarbital and the carotid artery
was cannulated with a polyethylene catheter connected to a transducer and a polygraph
recorder. Injections were made into the femoral artery.
Purification of Helodermatine: Benzamidine Sepharose Affinity Chromatogra-
phy. Lyophilized venom (100 mg) was dissolved in 0.1 M Tris/HCI, pH 7 .95
(starting buffer), and insoluble material was removed by centrifugation . The
clear supernatant was applied to a 10 ml (0 .9 X 15 cm) column of benzamidine-
Sepharose. The column was washed with 15 volumes of the same buffer and was
eluted by using a linear salt gradient from 0 to 0.8 M NaCl in a total volume of
300 ml. The results are presented in Fig. 1 .
Purification of Helodermatine: DEAF-Cellulose Anionic Exchange Chromatogra-
phy. Pooled active fractions from five independent benzamidine-Sepharose
chromatographies (A.4 in Fig . 1) were combined, dialyzed against starting buffer
(15 mM potassium phosphate, pH 7 .55), and applied to a 0.9 X 30 cm column
of DEAE-cellulose (DE 52 ; Whatman Inc .) equilibrated in the same buffer. The
column was washed with two volumes of starting buffer and developed using a
linear gradient from 0 to 0.3 M KCI in a total volume of 500 ml . The active
fractions were pooled, dialyzed vs. 50 mM (NH4) HCO3, and were lyophilized.
The results of the chromatography are presented in Fig. 2 and a summary of
the purification procedure is given in Table I .
Criteria of Purity.
￿
The purity of the helodermatine preparation was estab-
lished by four different independent methods: (a) SDS-PAGE of the reduced
protein followed by staining with Coomassie Brilliant Blue (Fig. 3); (b) SDS-
PAGE of the iodinated nonreduced and reduced protein followed by radioau-1838 HELODERMATINE
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FIGURE 2.
￿
DEAE-cellulose anionic exchange chromatography of fraction A.4 from Fig. 1 .
4 .5 ml of fraction A .4 from Fig. 1 were applied to the column. The flow was maintained at
30 ml/h. 2.5-ml fractions were collected. Fractions were pooled as indicated by horizontal
bars. Fraction A.4.2 was used for further characterization. Fractions A.4.1 and A.4.3, which
contained minor contamination, were recycled in the next batch of purification.
TABLE I
* Assuming E28a = 10
Assuming E28o = 25.8, as derived from the amino acid analysis of the pure protein.
Purification ofHelodermatinefrom Lyophilized H. h. horridum Venom
tography (Fig. 4); (c) SDS-PAGE of the nonreduced and reduced protein after
active site affinity labeling with DIFP (Fig. 5); and (d) identification of only one
amino acid in each step of the N-terminal amino acid sequence (Fig. 6).
Amino Acid Analysis.
￿
The results of the amino acid analysis are presented in
Table 11. There is no unusual or conspicuous feature in the amino acid compo-
sition . The A28o of a solution of 1 mg/ml helodermatine as determined by amino
acid analysis was found to be 2.58 .
NH2-Terminal Protein Sequence.
￿
The sequence of the 20 NH2-terminal amino
acids is presented in Fig. 6 and compared with the sequence ofporcine pancreatic
kallikrein (21), crotalase, a kallikrein-like enzyme from the venom of the diamond
back rattle snake Crotalus adamanteus (22) and kallikrein-like enzymes from
Crotalus atrox (23). There is a significant homology to all four enzymes, but the
closest (8 of 19 residues) is to porcine pancreatic kallikrein.
Enzymatic Properties.
￿
Both D-Pro-Phe-Arg pNa (S-2302) and D-Val-Leu-Arg
pNa (S-2266), originally developed, respectively, for human serum kallikrein and
glandular kallikrein proved to be excellent substrates for helodermatine . Kunitz-
type bovine pancreatic trypsin inhibitor (aprotinin, Trasylol) and soybean trypsin
inhibitor are strong competitive inhibitors of helodermatine . DIFP inactivated
helodermatine irreversibly in a time-dependent fashion consistent with a second-
Fraction Source of fraction Protein Specific activity
(BAEE)*
Recovery
of activity
mg U/mg
Whole venom Lyophilized venom 100 2.67 100
A.4 Benzamidine-Sepharose 9.1 20.02 81
A.4.2 DEAE-32 cellulose 6.4 22.64 (8.771) 55FIGURE 3 .
￿
SDS-PAGE of 5 jug of purified helodermatine under conditions described in the
text . The sample was reduced by boiling for 10 min in sample buffer containing 1% 2-ME.
Acrylamide concentration was7.5% .
FIGURE 4 .
￿
SDS-PAGE of '251-labeled helodermatine . 0.01 140 of sample were loaded per
well . NR, native sample denatured at room temperature in sample buffer ; R, sample denatured
andreduced by boiling for 5 min in presence of 10 mM DTT. The gelwasdriedand exposed
over night on XAR film, Eastman Kodak Co ., Rochester, NY .
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order rate constant ^ " 1/M . s. Active site titration with MUGB revealed a good
correlation between molarity calculated on the basis of available active sites or
on the basis ofMr and protein content . These experiments are summarized in
Table III. Helodermatine released 75% of the amount of kinin from human
HMW-kininogen, as human plasma kallikrein did in equivalent amounts and
otherwise identical conditions . Incubation of 40 ug single chain tPA with 2 ug
helodermatine (100 ),1 reaction volume, 60 min at 25°C) resulted in a 50%
conversion of single-chain tPA into double-chain tPA . Without addition of
helodermatine, the single-chain tPA preparation was perfectly stable (Fig . 7A).1840
Helodermatine
Crotalase b
Porcine Kalli-
krein o chain NHZ
HELODERMATINE
FIGURE 5 .
￿
SDS-PAGE of DIFP-labeled helodermatine . 1 leg of sample was loaded per well .
NR, native sample denatured at room temperature in sample buffer ; R, sample denaturedand
reduced by boiling for 5 min in presence of 10 mM DTT. The gel was processed for
fluorography, dried, and exposed to film as described (16) .
NH, - I1
￿
a1-Gly-Gl
￿
Gln Glu-Cy -Pro-Gln-Val-Ile His-Pro-T
C . atrox E I a
￿
NHZ Hi
￿
a1 -Gly -Gly-Asp -Glu-Cys-Asn-Ile-Asn-Glu-His
C . atrox E II a NHZ Hi
￿
al-Gly -Gly-Asp -Glu -Cys-Asn-Ile-Asn-Glu-His
NH2 -Val -~lly -Gly-Asp-Glu-Cys-Asn-Ile-Asn-Glu-His
Jly-G1 Arc, Glu-Cy -Glu-Lys As Ser His-Pro-Tr Gln al-A1
Discussion
p-Le G1 -Leu-XXX-Leu-XXX-f r
Leu-Val-Ala-Ile-Phe-Va Phe
Leu-Val-Ala-Il -Phe-Va -Ser
Leu-Val-A1 -Leu
FIGURE 6 .
￿
NH2-terminal sequence of helodermatine . Comparison with similar proteinases .
Regions of sequence identity are boxed (21-23) .
The enzyme neither coagulated fibrinogen, nor did it activate plasminogen (data
not shown) .
Effect on Rabbit Blood Pressure .
￿
The effect of helodermatine on the blood
pressure of an anesthetized rabbit is shown in Fig . 8 . If 40,ug ofhelodermatine
were incubated with 200 ug of aprotinin for 5 min at ambient temperature
before injection, the hypotensive effect was completely abolished (data not
shown) .
We describe a simple procedure for the purification of the major N-benzoyl-
L-arginine esterasefrom crude venomofH . h . horridum . Theprocedure compares
favorably, in terms of yield, speed, and final purity, to previously published
methods (5, 8) . The principal step consists of affinity chromatography on com-
mercially available benzamidine-Sepharose . The purity of the preparation ap-
pears well established by several criteria, notably the migration as a single band
in SDS-PAGE of the iodinated protein and the initial yield ofone terminal amino
acid residue obtained through the Edman degradation procedure . Affinity
labeling with DIFP established that the enzyme belongs to the serine proteinase
family . Several lines of evidence indicate a close relationship of this enzyme to
the kallikreins . Among them stands foremost the high efficiency in liberating the
vasoactive kinin from HMW-kininogen, the high catalytic efficiency by which
the substrateS-2302 and S-2266 are hydrolysed and the lowK; values arederivedALAGON ET AL.
TABLE II
Amino Acid Composition ofPurified Helodermatine
Amino acid compositions were calculated by taking the number of
residues per mole ofaspartic acid, glutamic acid, alanine, and leucine to
be,respectively, 57, 61, 20, and 41.
* Averages of duplicateanalyses.
Calculated by extrapolating to time 0 of hydrolysis.
TABLE III
Enzymatic Properties ofHelodermatine
Inhibitor
￿
K; (M)*
Aprotinin(Trasylol)
￿
2.8 x 10-e
Soybean trypsin inhibitor
￿
3.0 x 10-8
* Derived from Dixon plots, using S-2302 as competing substrate.
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from the interaction with aprotinin and soybean trypsin inhibitor. Finally, N-
terminal sequence analysis revealed a significant homology to kallikrein from
porcine pancreas and kallikrein-like enzymes from the venoms ofC. atrox and C.
adamanteus. The hypotensive shock almost immediately after bites of crotalid
snakes is most likely due to the kallikrein-like enzymes in the respective venoms
(23). In analogy, the hypotensive effect of heloderma venom after injection into
rabbits, already noted by Fleisher (24), is due to helodermatine, either alone or
in combination with other still unknown reagents, because we have clearly shown
Amino acid 20 h* 48 h* 72 h* Nearest
integer
Lysine 12.35 11 .89 12.11 12
Histidine 12.57 12.69 12.64 13
Arginine 25.59 26.63 25.43 26
Tryptophan ND ND ND ND
Aspartic acid 57.05 57.33 55.56 57
Threonine 39.25 36.47 33.23 42$
Serine 45.76 38.14 32.31 51t
Glutamic acid 61 .38 60.84 61 .47 61
Proline 34.62 32.69 33.68 34
Glycine 69.60 69.61 69.60 70
Alanine 19.61 19.19 20.40 20
Half-cystine 24.34 22.95 21 .56 23
Valine 42.16 44.40 45.08 45
Methionine 6.01 6.00 6.67 6
Isoleucine 35.36 38.83 39.00 39
Leucine 40.95 40.93 41.22 41
Tyrosine 22.72 21.97 21 .62 22
Phenylalanine 11.08 11.83 11.64 12
Glucosamine 8.51 3.36 0.94 11$
Substrate Km K., (1/s) K t/K. (1/M-s)
S-2302 16 1.31 81,900
S-2160 - 0.05 -
S-2227 - 0.37 -
S-2266 75 1.46 17,600
BASE 83 9.19 110,5001842 HELODERMATINE
FIGURE 7 . SDS-PAGE of (A) single-chain tPA incubated for 60 min at 25°C in 50 mM
Tris/HCI, pH 7.4 ; (B) single-chain tPA incubated in presence of 5% (wt/wt) helodermatine
under otherwise identical conditions . 15 Wg of sample were loaded per well . Polyacrylamide
concentration was 10% . H and L chain of tPA are indicated by arrows . Helodermatine is not
visible under the staining conditions used . NR and R, see footnote to Fig . 5 .
FIGURE 8 .
￿
Effect of helodermatine on the blood pressure of an anesthetized rabbit . Panels
A-D show the effect of the injection of 2, 4, 8, and 16 lAg/kg .ALAGON ET AL.
￿
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its hypotensive effect. In contrast to the snake enzymes, however, no thrombin-
like activity appears to be associated with this enzyme. The conversion of single-
chain into double-chain tPA by helodermatine may contribute to themaintenance
of a hyperfibrinolytic state at the site of a bite.
Recently, peptides related to glucagon and vasoactive intestinal peptide (VIP)
have been described (3) in the venom ofH. suspectum. Glandular kallikreins have
been associated with the processing of prohormone precursors (25). Thus,
another possible function of helodermatine might be the generation of pharma-
cologically active peptides from protein precursors in the venom.
We present for the first time a chemical and enzymatic characterization of a
kallikrein-like enzyme in the Sauria family. Further research will have to address
the question whether this enzyme is more related to the glandular or the serum
kallikreins. The M, of helodermatine is significantlyhigher than that of glandular
kallikreins (21) but lower than the M, of serum kallikrein . Like the glandular
kallikreins, helodermatine is strongly inhibited by aprotinin. It cleaves synthetic
peptide substrates, however, with similar kinetics as serum kallikrein. Our find-
ings are of possible relevance for the evolutionary history of the kallikrein/kinin
system or proteolytic regulatory systems in general.
Summary
We have purified and characterized the majorN-benzoyl-L-arginine ethyl ester
hydrolase from the venom ofHeloderma horridum horridum. The enzyme belongs
to the serine proteinase family, and its activity vs. peptide amide substrates and
human high-molecular-weight kininogen suggests a similarity to the family of
kallikreins. This interpretation is corroborated by its reactivity with the natural
inhibitors soybean trypsin inhibitor and Kunitz-type bovine pancreatic trypsin
inhibitor (aprotinin). Injection of the enzyme (2-16 ug/kg) into anesthetized
rabbits leads to a rapid dose-dependent transient decrease of the arterial blood
pressure. Like glandular kallikrein it specifically converts single-chain tissue type
plasminogen activator into its double chain form. In contrast to other kallikrein-
like enzymes from snake venoms it shows no thrombin-like or plasminogen
activator activity. The enzyme is a single-chain glycoprotein (M, 63,000). TheN-
terminal sequence revealed significant homology to pig pancreatic kallikrein and
to kallikrein like enzymes from Crotalus atrox and Crotalus adamanteus venom.
This enzyme, which we name Helodermatine, is the first purified from Sauria
with kallikrein-like properties.
We are indebted to Prof. J.-P. Guignard and Mme. N. Aubert for their generous help
with the rabbit blood pressure and Drs. Brigitte Dittmann and Hans Fritz for the rat
uterus assay. We thank Domnika von Zahn-Schleuning and Josette Guillemin for prepa-
ration of the manuscript.
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